Mantis Biotech: Digital Twins to Overcome Medical Data Limitations

Mantis Biotech is introducing an innovative approach to address one of the most persistent challenges in the medical sector: data availability and accessibility. The company focuses on creating "digital twins" of the human body, complex models that replicate anatomy, physiology, and behavior, with the goal of unlocking new frontiers in research and clinical development.

This emerging paradigm promises to revolutionize how medical professionals and researchers interact with patient information, providing a secure and controlled environment for analysis and experimentation. The ability to generate high-quality synthetic datasets is crucial in an era where data privacy and regulatory compliance are absolute priorities.

Creating Synthetic Datasets for Digital Twins

The core of Mantis's strategy lies in its ability to aggregate and process disparate data sources to generate synthetic datasets. These datasets do not contain real patient information but replicate their statistical properties and complex relationships, making them ideal for training artificial intelligence models and for simulation. The use of advanced machine learning techniques, including Large Language Models (LLMs) or specific generative models, is fundamental in this process to ensure that the synthetic data is realistic and useful.

Once created, these synthetic datasets are used to build "digital twins" of the human body. These virtual models are designed to faithfully represent the anatomy (structure), physiology (function), and behavior (responses to stimuli) of an individual or a population. The precision and granularity of these digital twins directly depend on the quality and richness of the initial synthetic data, requiring robust computing infrastructures for their generation and management.

Context and Infrastructure Implications

The problem of data availability in medicine is multifaceted, often linked to strict privacy regulations (such as GDPR), the fragmentation of information across different institutions, and the high costs associated with collecting and anonymizing real data. Synthetic datasets offer a powerful solution, allowing researchers to work with significant volumes of data without compromising patient privacy.

For organizations looking to leverage these technologies, the choice of deployment infrastructure is critical. The generation and management of complex synthetic datasets and digital twins require substantial computational resources, often with specific VRAM requirements for inference and training of generative models. The option of a self-hosted or air-gapped deployment can be particularly attractive to ensure data sovereignty and complete control over the processing environment, reducing risks associated with sharing data (even if synthetic) with third-party clouds. Evaluating the Total Cost of Ownership (TCO), which includes hardware, energy, cooling, and IT personnel costs, becomes a decisive factor compared to the operational expenses (OpEx) of cloud services.

Future Prospects and Data Control

The adoption of digital twins and synthetic datasets has the potential to significantly accelerate drug discovery, optimize treatment protocols, and personalize medicine to an unprecedented level. Imagine the possibility of virtually testing the efficacy of a new drug on thousands of digital twins before moving to clinical trials, reducing time and costs.

However, the success of these initiatives also depends on organizations' ability to maintain strict control over their data and processing pipelines. For those evaluating on-premise deployments, AI-RADAR offers analytical frameworks on /llm-onpremise to assess the trade-offs between self-hosted and cloud solutions, considering aspects such as security, compliance, and operational efficiency. The ability to autonomously manage the entire technology stack, from bare metal to application, will be a key factor for companies aiming to fully exploit the potential of digital twins in medicine.